Cargando…
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Activation of nuclear β-catenin and expression of its transcriptional targets promotes chronic myeloid leukemia (CML) progression, tyrosine kinase inhibitor (TKI) resistance, and leukemic stem cell self-renewal. We report that nuclear β-catenin plays a role in leukemia cell-intrinsic but not -extrin...
Autores principales: | Eiring, Anna M., Khorashad, Jamshid S., Anderson, David J., Yu, Fan, Redwine, Hannah M., Mason, Clinton C., Reynolds, Kimberly R., Clair, Phillip M., Gantz, Kevin C., Zhang, Tian Y., Pomicter, Anthony D., Kraft, Ira L., Bowler, Amber D., Johnson, Kara, Mac Partlin, Mary, O’Hare, Thomas, Deininger, Michael W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675686/ https://www.ncbi.nlm.nih.gov/pubmed/26202934 http://dx.doi.org/10.1038/leu.2015.196 |
Ejemplares similares
-
Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015) -
A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016) -
A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia
por: Woessner, David W., et al.
Publicado: (2015) -
Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia
por: Eiring, Anna M., et al.
Publicado: (2014) -
Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib
por: Qiang, Wang, et al.
Publicado: (2017)